News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xigen S.A. Closes Its Series A Financing Round With CHF 26 Million



10/19/2005 5:09:12 PM

LAUSANNE, Switzerland--(BUSINESS WIRE)--Sept. 6, 2005--Xigen S.A., a Swiss biotechnology company engaged in research and development of intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer, announced today the successful conclusion of its Swiss Francs 26m (21m USD) Series A financing round with Tilocor Life Sciences, Venture Incubator (VI) and Initiative Capital (IC) as investors.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES